Exicure

Exicure, Inc. is a biotechnology company that was focused on developing nucleic acid therapies targeting ribonucleic acid (RNA) for neurological disorders and hair loss. Their approach centered on their proprietary spherical nucleic acid (SNA™) platform, which consists of synthetic nucleic acid sequences densely radiating from a spherical core. This technology aimed to overcome the challenge of safe and effective delivery of nucleic acid therapeutics into cells and tissues. Exicure's headquarters are located in Chicago, Illinois, where they conducted their discovery and development efforts in a dedicated facility.

However, in September 2022, Exicure announced a significant reduction in force, suspension of preclinical activities, and halting of all research and development. This was followed by the company exploring strategic alternatives to maximize stockholder value. As a result, Exicure is no longer actively developing its own therapies, but is instead seeking to out-license its existing assets, such as cavrotolimod, a clinical-stage asset in immuno-oncology.

Exicure is a biotechnology company focused on developing nucleic acid therapies, specifically targeting ribonucleic acid (RNA), to address both genetic and non-genetic neurological disorders. They utilize a proprietary spherical nucleic acid (SNA™) platform, which overcomes the challenges of safe and effective delivery into cells and tissues, allowing them to develop a new class of immunomodulatory and gene silencing drugs.

Exicure promotes a fast-paced and innovative culture that values passion and dedication. They seek highly skilled and experienced employees who share their enthusiasm for driving their groundbreaking technology forward to benefit patients in need.